178 related articles for article (PubMed ID: 18451163)
21. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
22. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
[TBL] [Abstract][Full Text] [Related]
23. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
24. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
[TBL] [Abstract][Full Text] [Related]
25. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
26. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
29. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
30. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression.
Kim MK; Song JY; Koh DI; Kim JY; Hatano M; Jeon BN; Kim MY; Cho SY; Kim KS; Hur MW
J Biol Chem; 2019 Jan; 294(1):299-313. PubMed ID: 30409904
[TBL] [Abstract][Full Text] [Related]
31. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
32. The role of BCL6 in lymphomas and routes to therapy.
Wagner SD; Ahearne M; Ko Ferrigno P
Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
[TBL] [Abstract][Full Text] [Related]
33. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
34. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
[TBL] [Abstract][Full Text] [Related]
35. Rewiring cancer drivers to activate apoptosis.
Gourisankar S; Krokhotin A; Ji W; Liu X; Chang CY; Kim SH; Li Z; Wenderski W; Simanauskaite JM; Yang H; Vogel H; Zhang T; Green MR; Gray NS; Crabtree GR
Nature; 2023 Aug; 620(7973):417-425. PubMed ID: 37495688
[TBL] [Abstract][Full Text] [Related]
36. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
37. iASPP inhibition: increased options in targeting the p53 family for cancer therapy.
Bell HS; Ryan KM
Cancer Res; 2008 Jul; 68(13):4959-62. PubMed ID: 18593889
[TBL] [Abstract][Full Text] [Related]
38. A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.
Bosch R; Dieguez-Gonzalez R; Céspedes MV; Parreño M; Pavón MÁ; Grañena A; Sierra J; Mangues R; Casanova I
Blood; 2011 Oct; 118(16):4411-20. PubMed ID: 21868575
[TBL] [Abstract][Full Text] [Related]
39. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma.
McCluggage WG; Catherwood M; Alexander HD; McBride HA; Smith ME; Morris TC
Histopathology; 2002 Nov; 41(5):414-20. PubMed ID: 12405909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
